The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Extended cohort study of OPB51602, a novel inhibitor of STAT3/5 activation, in non-small cell lung carcinoma.
Joline Si Jing Lim
No relevant relationships to disclose
Andrea Li Ann Wong
No relevant relationships to disclose
Ross A. Soo
No relevant relationships to disclose
Soo-Chin Lee
No relevant relationships to disclose
Patrick Marban
No relevant relationships to disclose
Li Ren Kong
No relevant relationships to disclose
Brendan Pang
No relevant relationships to disclose
Richie Chuan Teck Soong
No relevant relationships to disclose
Daniel Shao-Weng Tan
No relevant relationships to disclose
David Shao Peng Tan
No relevant relationships to disclose
Kumi Higuchi
Research Funding - Otsuka
Masaaki Motoyama
Research Funding - Otsuka
Takeshi Tsunoda
Research Funding - Otsuka
Boon C. Goh
Consultant or Advisory Role - Otsuka
Research Funding - Otsuka